Therefore, targeting cMyBP-C with drugs that mimic phosphorylation and/or perturb its interactions with actin or myosin is a promising approach to improving cardiac muscle function in HF and cardiomyopathy. The gene discussed is MYBPC3; the disease is cardiomyopathy.